UPMC Cancer Center - Pittsburgh
Welcome,         Profile    Billing    Logout  
 8 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tawbi, Hussein A
NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting
2
88
US
Fianlimab, Cemiplimab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals
Advanced Melanoma
09/27
09/27
NCT02816021: Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma

Active, not recruiting
2
24
US
Azacitidine, 5-azacytidine, 5-aza, Vidaza, 5-AZC, Ladakamycin, NSC-102816, Azacytidine, Pembrolizumab, Keytruda, MK-3475, SCH-900475
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Celgene
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
02/25
02/26
NCT03131908: Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Active, not recruiting
1/2
27
US
GSK2636771, Pembrolizumab, Keytruda, MK-3475, SCH-900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH), Merck Sharp & Dohme LLC, GlaxoSmithKline
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
12/25
12/25
NCT01366144: Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Active, not recruiting
1
94
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pharmacological Study, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI), Abbott
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
11/17
03/25
Syntrix-SX682-Melanoma-101, NCT03161431: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Checkmark Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Oct 2020 - Oct 2020: Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Recruiting
1
77
US
SX-682, Pembrolizumab, KEYTRUDA
Syntrix Biosystems, Inc., Massachusetts General Hospital, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Mayo Clinic, University of Rochester, M.D. Anderson Cancer Center, University of Miami
Melanoma Stage III, Melanoma Stage IV
06/25
06/26
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Active, not recruiting
1
16
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Metastatic Melanoma, Metastasis to Brain
06/24
06/25

Download Options